With this combined treatment approach, we found strong suggestions for synergistic activity between the standard-of-care chemotherapy and the immunotherapies to improve the OS of patients with IDH1 wild-type MGMT promoter unmethylated adults with GBM [29]. Here, IDH1 is linked to glioblastoma.